Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...

RBC Capital analyst Luca Issi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $95.00. The ...

“These are scams,” said Kenny Biddle, the chief investigator for the Center of Inquiry, an organization devoted to defending ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million ...

Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and ...

Cambridge, USA-based Korro Bio has entered a collaboration with Denmark’s Novo Nordisk to advance the discovery and ...

Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on Korro Bio (KRRO – Research Report) and keeping the price target at ...

Korro Bio Inc. has established a collaboration with Novo Nordisk A/S to advance the discovery and development of new genetic medicines, initially to treat cardiometabolic diseases. The collaboration ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative ...